A chylothorax refers to the presence of chylous fluid in the pleural space often as a result of obstruction or disruption to the thoracic duct. It may be congenital or acquired.
Chylothoraces may present with variable pleural fluid appearance and biochemical characteristics; they are usually exudative. A non-milky appearance is common. Chylous effusions can rarely be transudative (especially in patients with cirrhosis).
It can be due to direct injury to the lymphatic ducts or due to obstruction of the ducts and fragile collateral formations which are prone to spontaneous rupture. Common causes include:
- lymphoma: generally thought to be the most common non-traumatic cause
- iatrogenic: post thoracic and abdominal surgery, in particular esophagectomy and block dissection of the neck, are considered the most common etiologies in the developed world
- non-surgical trauma, e.g. thoracic duct laceration due to thoracic vertebral fractures
Other less common causes are:
- idiopathic/cryptogenic: most common in neonatal period
- congenital thoracic duct ectasia
- fibrosing/sclerosing mediastinitis
- nephrotic syndrome
- tuberous sclerosis
- sarcoidosis (rare) 3
- Gorham disease (rare; shoulder girdle/thoracic bone osteolysis) 6
In a neonate:
- congenital heart disease
- Turner syndrome
- Noonan syndrome
- Down syndrome
- pulmonary sequestration (extralobar)
- tracheo-esophageal fistula
Increased density of hemithorax due to ipsilateral pleural effusion. Less commonly, chylothorax can be bilateral.
Simple appearing pleural effusion without debris or septations.
Most of the time, it appears as a simple fluid collection of near water density.
Treatment and prognosis
Low output (less than 1000 mL/day) is treated conservatively with a low-fat diet. High output usually treated with open or video-assisted ligation. Alternatively, thoracic duct embolization can be performed by an interventional radiologist with a comparable outcome to surgical ligation. Medical therapy with octreotide (somatostatin analog) has been shown to be useful adjunctive therapy in the treatment of post operative chyle leak following thoracic duct injury 11.
- 1. Talwar A, Lee HJ. A contemporary review of chylothorax. Indian J Chest Dis Allied Sci. 50 (4): 343-51. Pubmed citation
- 2. Fairfax AJ, McNabb WR, Spiro SG. Chylothorax: a review of 18 cases. Thorax. 1986;41 (11): 880-5. doi:10.1136/thx.41.11.880 - Free text at pubmed - Pubmed citation
- 3. Jarman PR, Whyte MK, Sabroe I et-al. Sarcoidosis presenting with chylothorax. Thorax. 1995;50 (12): 1324-5. Thorax (link) - Free text at pubmed - Pubmed citation
- 4. Büttiker V, Fanconi S, Burger R. Chylothorax in children: guidelines for diagnosis and management. Chest. 1999;116 (3): 682-7. doi:10.1378/chest.116.3.682 - Pubmed citation
- 5. Doerr CH, Allen MS, Nichols FC et-al. Etiology of chylothorax in 203 patients. Mayo Clin. Proc. 2005;80 (7): 867-70. doi:10.4065/80.7.867 - Pubmed citation
- 6. Collins J. Case 92: Gorham syndrome. Radiology. 2006;238 (3): 1066-9. doi:10.1148/radiol.2383032126 - Pubmed citation
- 7. Maldonado F, Hawkins FJ, Daniels CE, Doerr CH, Decker PA, Ryu JH. Pleural fluid characteristics of chylothorax. Mayo Clinic proceedings. 84 (2): 129-33. doi:10.1016/S0025-6196(11)60820-3 - Pubmed
- 8. McGrath EE, Blades Z, Anderson PB. Chylothorax: aetiology, diagnosis and therapeutic options. Respiratory medicine. 104 (1): 1-8. doi:10.1016/j.rmed.2009.08.010 - Pubmed
- 9. Schild HH, Strassburg CP, Welz A, Kalff J. Treatment options in patients with chylothorax. Deutsches Arzteblatt international. 110 (48): 819-26. doi:10.3238/arztebl.2013.0819 - Pubmed
- 10. Hoffer EK, Bloch RD, Mulligan MS, Borsa JJ, Fontaine AB. Treatment of chylothorax: percutaneous catheterization and embolization of the thoracic duct. AJR. American journal of roentgenology. 176 (4): 1040-2. doi:10.2214/ajr.176.4.1761040 - Pubmed
- 11. Markham KM, Glover JL, Welsh RJ, Lucas RJ, Bendick PJ. Octreotide in the treatment of thoracic duct injuries. (2000) The American surgeon. 66 (12): 1165-7. Pubmed